Pfizer Inc. (NYSE:PFE) Shares Sold by Brown Brothers Harriman & Co.

Brown Brothers Harriman & Co. decreased its holdings in shares of Pfizer Inc. (NYSE:PFE) by 2.8% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 204,695 shares of the biopharmaceutical company’s stock after selling 5,911 shares during the quarter. Brown Brothers Harriman & Co.’s holdings in Pfizer were worth $5,727,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of PFE. Olistico Wealth LLC acquired a new position in shares of Pfizer during the 2nd quarter worth approximately $25,000. MFA Wealth Advisors LLC acquired a new position in Pfizer during the second quarter worth $29,000. Creekmur Asset Management LLC purchased a new stake in Pfizer in the 4th quarter valued at $32,000. Trivant Custom Portfolio Group LLC increased its stake in shares of Pfizer by 100.0% in the 1st quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 600 shares during the last quarter. Finally, Financial Connections Group Inc. purchased a new position in shares of Pfizer during the 2nd quarter worth $34,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

PFE has been the topic of a number of analyst reports. UBS Group lifted their target price on shares of Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 31st. Barclays lifted their price target on shares of Pfizer from $30.00 to $32.00 and gave the company an “equal weight” rating in a research report on Wednesday, July 31st. Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a report on Monday. Daiwa America raised Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research note on Wednesday, August 7th. Finally, StockNews.com upgraded Pfizer from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Eight research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Pfizer currently has a consensus rating of “Moderate Buy” and a consensus price target of $34.54.

Pfizer Price Performance

Shares of PFE opened at $30.07 on Tuesday. The company has a market cap of $170.40 billion, a P/E ratio of -501.08, a PEG ratio of 1.02 and a beta of 0.68. Pfizer Inc. has a fifty-two week low of $25.20 and a fifty-two week high of $34.12. The company has a quick ratio of 0.60, a current ratio of 0.86 and a debt-to-equity ratio of 0.65. The firm’s 50 day moving average price is $29.26 and its 200 day moving average price is $28.15.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, topping analysts’ consensus estimates of $0.46 by $0.14. The business had revenue of $13.28 billion for the quarter, compared to analyst estimates of $12.96 billion. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. The company’s revenue was up 2.1% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.67 earnings per share. On average, research analysts forecast that Pfizer Inc. will post 2.66 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 3rd. Stockholders of record on Friday, July 26th were given a dividend of $0.42 per share. This represents a $1.68 dividend on an annualized basis and a dividend yield of 5.59%. The ex-dividend date was Friday, July 26th. Pfizer’s dividend payout ratio is presently -2,799.53%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.